Medco shareholders slow down Repligen deal


A group of Medco Research Inc. stockholders are balking at the proposed financial terms of the merger between MRE and Repligen Corp. As a result, the companies announced on Friday that they are negotiating a valuation for RGEN below the $51.5 million proposed in the nonbinding letter of intent signed in May.

The investors, led

Read the full 568 word article

How to gain access

Continue reading with a
two-week free trial.